PTLA Portola Pharmaceuticals Inc.

50.29
-0.21  -0%
Previous Close 50.50
Open 50.50
Price To book 26.19
Market Cap 2907840117
Shares 57,821,438
Volume 533,972
Short Ratio 2.67
Av. Daily Volume 1,026,063

SEC filingsSee all SEC filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 171083390
  2. 8-K - Current report 171083335
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171079600
  4. 8-K - Current report 171079409
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018566

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA Approval noted June 23, 2017.
Bevyxxa (betrixaban)
Venous thromboembolism (VTE) Prevention
Phase 2 enrollment commenced May 2016. Interim data released June 15, 2017 - noted CLL/SLL 67% partial responese rate + two patient deaths.
Cerdulatinib (PRT2070)
Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer
CRL August 17 2016. New PDUFA date February 2, 2018.
Andexanet alfa
Factor Xa inhibitor reversal agent

Latest News

  1. Portola Pharmaceuticals Supports 2017 World Thrombosis Day Campaign to Raise Awareness about the Persistent Risk of Blood Clots
  2. See what the IHS Markit Score report has to say about Portola Pharmaceuticals Inc.
  3. Portola Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  4. Cramer's lightning round: Portola's no one-trick pony
  5. Today's Research Reports on Trending Tickers: Portola Pharmaceuticals and Synchronoss Technologies
  6. Is It The Right Time To Buy Portola Pharmaceuticals Inc (PTLA)?
  7. Portola Shares Lower After Pricing Stock Offering - Biotech Movers
  8. Portola Announces Pricing of Public Offering of Common Stock
  9. Portola Pharmaceuticals Announces Proposed Offering of Common Stock
  10. Glancy Prongay & Murray LLP Commences Investigation on Behalf of Portola Pharmaceuticals, Inc. Investors (PTLA)
  11. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Portola Pharmaceuticals, Inc.
  12. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Portola Pharmaceuticals Inc. (PTLA)
  13. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Portola Pharmaceuticals Inc. - PTLA
  14. Today's Research Reports on Trending Tickers: Pulmatrix Inc. and Portola Pharmaceuticals Inc.
  15. Portola Pharmaceuticals to Present at the 2017 Morgan Stanley Global Healthcare Conference
  16. Reminder: Portola Pharmaceuticals to Host Webcast and Conference Call Today, Tuesday, Sept. 5 to Provide Further Details on Bevyxxa® (betrixaban) Launch

SEC Filings

  1. 424B5 - Prospectus [Rule 424(b)(5)] 171083390
  2. 8-K - Current report 171083335
  3. 424B5 - Prospectus [Rule 424(b)(5)] 171079600
  4. 8-K - Current report 171079409
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 171018566
  6. 8-K - Current report 171018222
  7. SC 13G - Statement of acquisition of beneficial ownership by individuals 17967637
  8. 8-K - Current report 17919270
  9. CT ORDER - Confidential treatment order 17894817
  10. 10-Q - Quarterly report [Sections 13 or 15(d)] 17823685